Based in Geneva, Switzerland, Addex Therapeutics Ltd is a biotechnology company focused on discovering and developing small-molecule pharmaceuticals targeting G-protein coupled receptors and enzymes for neurological disorders. The company's lead candidate, Dipraglurant, is in phase 1 clinical development for post-stroke and traumatic brain injury recovery, as well as Parkinson's disease levodopa-induced dyskinesia. The pipeline also includes ADX71149, a metabotropic glutamate receptor subtype 2 positive allosteric modulator being evaluated for central nervous system indications, and GABAB positive allosteric modulators in development for pain, anxiety, addiction, cough, and overactive bladder.
Addex operates through partnerships with established pharmaceutical companies. The company holds a license and collaboration agreement with Janssen Pharmaceuticals for mGlu2 PAM compound development, and a license and research agreement with Indivior PLC for GABAB PAM compounds targeting addiction and other CNS diseases. These partnerships form the primary revenue streams, structured around milestone payments and potential royalties on commercialized products.
The company operates with a minimal employee base of two full-time staff, reflecting a lean structure typical of early-stage biotechnology firms heavily reliant on external partnerships and contractors for research and development activities. Addex was incorporated in Switzerland and listed on Nasdaq, with its operations and headquarters remaining in Geneva.
No 10-K filings found.